Deferoxamine
Clinical data | |
---|---|
Trade names | Desferal |
Other names | desferrioxamine B, desferoxamine B, DFO-B, DFB ,N'-[5-(Acetyl-hydroxy-amino)pentyl]-N-[5-[3-(5-aminopentyl-hydroxy-carbamoyl) propanoylamino]pentyl]-N-hydroxy-butane diamide |
AHFS/Drugs.com | Monograph |
Routes of administration |
|
ATC code | |
Pharmacokinetic data | |
Elimination half-life | 6 hours |
Identifiers | |
| |
JSmol) | |
| |
|
Deferoxamine (DFOA), also known as desferrioxamine and sold under the brand name Desferal, is a medication that binds
Common side effects include pain at the site of injection, diarrhea, vomiting, fever,
Deferoxamine was approved for medical use in the United States in 1968.[1] It is on the World Health Organization's List of Essential Medicines.[6]
Medical uses
Deferoxamine is used to treat acute
Administration for chronic conditions is generally accomplished by
Some published manuscripts suggesting the use of deferoxamine for patients diagnosed with COVID-19 because of the high level of ferritin among them.[11][12]
Adverse effects
It is unclear if use during pregnancy is safe for the baby.[3]
Chronic use of deferoxamine may increase the risk of
Chronic use of deferoxamine may cause ocular symptoms,
Mechanism
Deferoxamine is produced by removal of the trivalent iron moiety from ferrioxamine B, an iron-bearing
Research
Deferoxamine is being studied as a treatment for spinal cord injury[18] and intracerebral hemorrhage.[19][20] It is also used to induce hypoxia-like environment in mesenchymal stem cells.[21][22]
Since the terminal amine group of Deferoxamine does not participate in metal chelation, it has been used to immobilize Deferoxamine to surfaces and substrates for various industrial and biomedical applications.[23]
See also
References
- ^ a b c d e f "Deferoxamine Mesylate". The American Society of Health-System Pharmacists. Archived from the original on 21 December 2016. Retrieved 8 December 2016.
- ISBN 9789241547659.
- ^ a b "Deferoxamine (Desferal) Use During Pregnancy". www.drugs.com. Archived from the original on 21 December 2016. Retrieved 13 December 2016.
- ^ ISBN 978-1-4557-4041-3. Archivedfrom the original on 2016-12-20.
- S2CID 37277528.
- hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
- PMID 22424293.
- PMID 29635754.
- S2CID 22425032.
- PMID 29566000.
- PMID 32607779.
- PMC 8108185.
- PMID 29201313.
- S2CID 232049825.
- PMID 8389019.
- PMID 17850672.
- PMID 15153529.
- ^ "Public summary of opinion on orphan designation: Deferoxamine mesylate for the treatment of traumatic spinal cord injury". Committee for Orphan Medicinal Products. European Medicines Agency. 3 October 2013. Archived from the original on 2013-07-17.
- PMID 21102602.
- PMID 32423330.
- PMID 16814746.
- PMID 16527254.
- .